Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP

- PMLiVE

Amgen invests $200m in Singapore monoclonal antibody facility

New manufacturing plant will produce both clinical and commercial products

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Amgen signs $180m nanotechnology cancer deal

Will combine BIND Biosciences' tissue-targeting technology with a molecularly-targeted drug

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

Novartis building

Novartis’ Exjade gets EU approval for thalassaemia

First oral treatment for condition characterised by red blood cell problems and anaemia

- PMLiVE

Amgen offers $762m to end Aranesp lawsuits

Pleads guilty to illegal marketing of anaemia drug

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

Amgen appoints CEO Robert Bradway to chair of board

Replaces Kevin Sharer who retires

- PMLiVE

Amgen continues spending spree, acquires deCode Genetics

Will pay $415m for Icelandic genetic information firm

- PMLiVE

Novartis calls for improvements to UK clinical trial system

Says cost of running studies in the country undermines its attractiveness

Novartis building

Novartis to issue stark warning to UK at crisis meeting

Says UK needs to address decline in pharma R&D

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links